Bicara Therapeutics BCAX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $33M+33.1% | $24.8M-27.7% | $34.3M+72.4% | ||
| $12.74M+56.7% | $8.13M+5.6% | $7.7M+6.7% | $7.22M-3.2% | $7.46M+10.4% | ||
| $60.24M+46.5% | $41.12M+1.1% | $40.68M+27.0% | $32.02M-23.4% | $41.79M+56.9% | ||
| -$60.24M-46.5% | -$41.12M-1.1% | -$40.68M-27.0% | -$32.02M+23.4% | -$41.79M-56.9% | ||
| $4.08M+7.8% | $3.79M-13.6% | $4.39M-6.3% | $4.68M-6.6% | $5.01M-14.5% | ||
| -$56.16M-50.4% | -$37.33M-2.9% | -$36.29M-32.8% | -$27.34M+25.7% | -$36.77M-77.0% | ||
| $52K-1.9% | $53K+32.5% | $40K-23.1% | $52K-27.8% | $72K-61.3% | ||
| -$56.21M-50.4% | -$37.39M-2.9% | -$36.33M-32.6% | -$27.39M+25.7% | -$36.85M-75.8% | ||
| -$0.93-36.8% | -$0.68-1.5% | -$0.67-34.0% | -$0.50+26.5% | -$0.68— | ||
| -$60.2M-46.5% | -$41.08M-1.1% | -$40.65M-27.0% | -$32M+23.4% | -$41.77M-56.9% | ||
| -$60.24M-46.5% | -$41.12M-1.1% | -$40.68M-27.0% | -$32.02M+23.4% | -$41.79M-56.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Bicara Therapeutics profitable?
- Bicara Therapeutics is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months.
- What is Bicara Therapeutics's earnings per share?
- Bicara Therapeutics's diluted EPS over the trailing twelve months is $-2.78.
- Where does Bicara Therapeutics's income statement data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.